Robert Gordon, MD
Cardiovascular Disease · Evanston, ILNPI 1417974973
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.9% of the total. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $130.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Cvrx, Inc.$3K
- Abiomed$3K
- Novartis$3K
- Akcea Therapeutics, Inc.$2K
- Abbott$839
- plus $2K from 18 others
Across 88 payments — averaging $4462.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$199K
- Abbott$102K
- AstraZeneca$57K
- E.r. Squibb & Sons, L.L.C.$24K
- Novartis$11K
What the payments were for
- Consulting fees$10,36352%
- Speaking & faculty fees$3,75019%
- Travel & lodging$3222%
- Food & beverage$5,36627%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 18 | $5,146 |
| Cvrx, Inc. | 7 | $3,492 |
| Abiomed | 16 | $3,258 |
| Novartis | 28 | $3,011 |
| Akcea Therapeutics, Inc. | 4 | $2,191 |
| Abbott | 20 | $839 |
| AstraZeneca | 5 | $344 |
| Novo Nordisk | 7 | $309 |
| Bayer | 9 | $207 |
| Medtronic | 3 | $205 |
| Alnylam Pharmaceuticals Inc. | 5 | $141 |
| Merck | 6 | $127 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $104 |
| Edwards Lifesciences | 1 | $84 |
| Pfizer | 2 | $74 |
| Lexicon Pharmaceuticals, Inc. | 4 | $71 |
| Bridgebio Pharma, Inc. | 2 | $67 |
| Lilly USA, LLC | 2 | $41 |
| Scpharmaceuticals Inc. | 2 | $38 |
| Boehringer Ingelheim | 1 | $33 |
| Boston Scientific | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Corcept Therapeutics | 1 | $26 |
| Angiodynamics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$3,365
- Impella$2,885
- ENTRESTO$2,363
- TEGSEDI$2,000
- HeartMate 3 Left Ventricular Dev$170
- LEQVIO$136
- CARDIOMEMS$122
- LINQ II$117
- BRILINTA$115
How this compares
$19,879 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 108 | $2,553,403 |
| EntrestoSacubitril/Valsartan | 824 | $1,109,251 |
| CamzyosMavacamten | 81 | $663,064 |
| FarxigaDapagliflozin Propanediol | 489 | $554,233 |
| EliquisApixaban | 391 | $547,402 |
| JardianceEmpagliflozin | 447 | $540,225 |
| OzempicSemaglutide | 194 | $291,392 |
| Orenitram ErTreprostinil Diolamine | 24 | $192,496 |
| XareltoRivaroxaban | 88 | $127,910 |
| MounjaroTirzepatide | 39 | $73,719 |
| LokelmaSodium Zirconium Cyclosilicate | 56 | $71,522 |
| Repatha SyringeEvolocumab | 71 | $59,795 |
| KerendiaFinerenone | 44 | $56,531 |
| Repatha SureclickEvolocumab | 52 | $49,078 |
| BrilintaTicagrelor | 34 | $38,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $74 | $3,100,805499 claims |
| NovartisEntresto | $3,011 | $1,109,251824 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $344 | $663,957579 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $5,146 | $663,06481 claims |
| Boehringer IngelheimJardiance | $33 | $540,225447 claims |
| Novo NordiskOzempic, Wegovy | $309 | $325,523216 claims |
| Lilly USA, LLCMounjaro, Trulicity | $41 | $111,06866 claims |
| BayerKerendia | $207 | $56,53144 claims |
| MerckVerquvo, Januvia | $127 | $43,90035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Evanston
- Amit PursnaniEvanston$115K
- Nikhil NarangEvanston$114K
- Jamil DihuEvanston$83K
- Eileen GajoEvanston$36K
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.